61MA Stock Overview
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 61MA from our risk checks.
MedCap AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr36.70 |
| 52 Week High | kr36.75 |
| 52 Week Low | kr20.95 |
| Beta | 0.66 |
| 1 Month Change | 13.62% |
| 3 Month Change | 11.72% |
| 1 Year Change | 44.20% |
| 3 Year Change | 56.17% |
| 5 Year Change | n/a |
| Change since IPO | 89.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 61MA | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 3.1% | 0.3% | -0.5% |
| 1Y | 44.2% | -15.0% | 2.5% |
Return vs Industry: 61MA exceeded the German Life Sciences industry which returned -14.8% over the past year.
Return vs Market: 61MA exceeded the German Market which returned 1.8% over the past year.
Price Volatility
| 61MA volatility | |
|---|---|
| 61MA Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 61MA has not had significant price volatility in the past 3 months.
Volatility Over Time: 61MA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 514 | Anders Dahlberg | www.medcap.se |
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe.
MedCap AB (publ) Fundamentals Summary
| 61MA fundamental statistics | |
|---|---|
| Market cap | €542.07m |
| Earnings (TTM) | €14.78m |
| Revenue (TTM) | €137.31m |
36.7x
P/E Ratio3.9x
P/S RatioIs 61MA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 61MA income statement (TTM) | |
|---|---|
| Revenue | kr1.60b |
| Cost of Revenue | kr661.00m |
| Gross Profit | kr938.70m |
| Other Expenses | kr766.50m |
| Earnings | kr172.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | 11.63 |
| Gross Margin | 58.68% |
| Net Profit Margin | 10.76% |
| Debt/Equity Ratio | 11.1% |
How did 61MA perform over the long term?
See historical performance and comparison